Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs USA Rare Earth Inc. Class A Common Stock (USAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs USA Rare Earth Inc. Class A Common Stock — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.78 (market cap $2.51B), while USA Rare Earth Inc. Class A Common Stock trades at $10.15 (market cap $4.23B). The key difference: USA Rare Earth Inc. Class A Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, USA Rare Earth Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SELLAS Life Sciences Group Inc. Common Stock for 0 Days and USA Rare Earth Inc. Class A Common Stock for 0 Days on average.
| SLS | USAR | |
|---|---|---|
Market Cap | $2.51B | $4.23B |
Volume | 6,359,048 | 13,677,660 |
Sector | Health | Basic Materials |
52-Week High | $15.46 | $33.68 |
52-Week Low | $1.39 | $10.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.37B | $2.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
USA Rare Earth (USAR) trades at $11.265, down 4.7% today and near its 52-week low, reflecting persistent sector pressure. The company shows severe financial strain with a net income margin of -2,159.3% and negative cash flow from operations, though analyst consensus remains unanimously bullish with a $34.57 price target. Recent news highlights strategic investments in a $1.2 billion South Carolina facility and a $2.8 billion Brazil acquisition to build a mine-to-magnet supply chain, positioning it for long-term growth amid U.S. critical mineral initiatives.
The stock presents high risk due to extreme losses and cash burn but offers speculative upside if government funding and project milestones materialize. Key risks include execution challenges, reliance on future financing, and sector volatility. Investors should weigh the bullish analyst outlook against the company's current financial instability and macroeconomic headwinds affecting rare earth markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About USA Rare Earth Inc. Class A Common Stock
USA Rare Earth is building an integrated rare earth and permanent magnet supply chain spanning mining, metal and alloy production, and magnet manufacturing, with assets including the Round Top heavy rare earth deposit in Texas, a magnet manufacturing facility in Stillwater, Oklahoma, and metal-and-alloy producer Less Common Metals.
Read more on USAR →
